| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802203203015 | 220320301 | DOXORUBIN INJ.SOL 10MG/5ML VIAL BTx 1 VIAL x 5 ML | 4.22 | 4.43 | 6.11 |
| 05/2018 | 2802203205019 | 220320501 | DOXORUBIN INJ.SOL 50MG/25ML VIAL BTx1 VIALx25 ML | 10.68 | 11.20 | 15.43 |
For the treatment of Koposi's sarcome connected to AIDS.
Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
LD<sub>50</sub>=21800 ug/kg (rat, subcutaneous)
55 hours
Plasma clearance is in the range 324 to 809 mL/min/m2 and is predominately by metabolism and biliary excretion.
* 324-809 mL/min/m2 * 1088 mL/min/m2 [Men] * 433 mL/min/m2 [Women] * 1540 mL/min/m2 [children greater than 2 years of age receiving administration of 10 to 75 mg/m2 doses] * 813 mL/min/m2 [infants younger than 2 years of age receiving administration of 10 to 75 mg/m2 doses]